Cangene Corporation today announces that it has submitted a Marketing Authorization Application ("MAA") for HepaGam B (Human Hepatitis B Immunoglobulin) Solution for Infusion or Injection to the European Medicines Agency ("EMEA"). The indications included in the MAA are immunoprophylaxis of hepatitis B and prevention of hepatitis B virus recurrence after liver transplantation in patients who are positive for hepatitis B surface antigen.
The details can be read here.
No comments:
Post a Comment